Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy

Brain Dev. 2011 Apr;33(4):289-93. doi: 10.1016/j.braindev.2010.06.008. Epub 2010 Jul 13.

Abstract

Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection. Recent observations suggest that levetiracetam is both safe and effective against post-stroke seizures. In this review, the potential neuroprotective role in brain ischemia and the therapeutic implications of levetiracetam in post-stroke epilepsy are discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Anticonvulsants / therapeutic use*
  • Brain Ischemia / drug therapy
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Epilepsy / etiology
  • Epilepsy / prevention & control*
  • Humans
  • Levetiracetam
  • Neuroprotective Agents / therapeutic use*
  • Piracetam / analogs & derivatives*
  • Piracetam / therapeutic use
  • Stroke / complications*

Substances

  • Anticonvulsants
  • Neuroprotective Agents
  • Levetiracetam
  • Piracetam